

University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln

Faculty Publications from the Department of
Electrical and Computer Engineering

Electrical & Computer Engineering, Department of

2008

Proteomic Identification of Interleukin-2 Therapy Response in Metastatic Renal Cell Cancer

Jon Jones

Harvard Medical School, jjones6@bidmc.harvard.edu

Hasan H. Otu

University of Nebraska-Lincoln, hotu2@unl.edu

Franck Grall

Harvard Medical School

Dimitrios Spentzos

Harvard Medical School

Handan Can

Harvard Medical School

See next page for additional authors

Follow this and additional works at: <http://digitalcommons.unl.edu/electricalengineeringfacpub>



Part of the [Computer Engineering Commons](#), and the [Electrical and Computer Engineering Commons](#)

Jones, Jon; Otu, Hasan H.; Grall, Franck; Spentzos, Dimitrios; Can, Handan; Aivado, Manuel; Belldegrun, Arie S.; Pantuck, Allan J.; and Libermann, Towia A., "Proteomic Identification of Interleukin-2 Therapy Response in Metastatic Renal Cell Cancer" (2008). *Faculty Publications from the Department of Electrical and Computer Engineering*. 440.
<http://digitalcommons.unl.edu/electricalengineeringfacpub/440>

This Article is brought to you for free and open access by the Electrical & Computer Engineering, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Faculty Publications from the Department of Electrical and Computer Engineering by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors

Jon Jones, Hasan H. Otu, Franck Grall, Dimitrios Spentzos, Handan Can, Manuel Aivado, Arie S. Beldegrun, Allan J. Pantuck, and Towia A. Libermann

Published in final edited form as:

J Urol. 2008 February ; 179(2): . doi:10.1016/j.juro.2007.09.016.

Proteomic Identification of Interleukin-2 Therapy Response in Metastatic Renal Cell Cancer

Jon Jones, M.D.^{1,4}, Hasan H. Otu, Ph.D.^{1,2,6,*}, Franck Grall, Ph.D.^{1,*}, Dimitrios Spentzos, M.D., M.M.Sc.^{1,2,3}, Handan Can, Ph.D.^{2,6}, Manuel Aivado, M.D.¹, Arie S. Belldegrun, M.D.⁵, Allan J. Pantuck, M.D.^{5,**}, and Towia A. Libermann, Ph.D.^{1,2}

¹Beth Israel Deaconess Medical Center (BIDMC) Genomics Center and Dana Farber/Harvard Cancer Center Cancer Proteomics Core, 4 Blackfan Circle, Boston, Massachusetts 02115

²Bioinformatics Core of BIDMC Genomics Center, Beth Israel Deaconess Medical Center and Harvard Medical School, 4 Blackfan Circle, Boston, Massachusetts 02115

³Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA 330 Brookline Ave, Boston, Massachusetts 02115

⁴Department of Urology and Pediatric Urology, Johann Wolfgang Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany

⁵University of California-Los Angeles Kidney Cancer Program, Departments of Urology and Medicine, Jonsson Comprehensive Cancer Center and the David Geffen School of Medicine at UCLA, Los Angeles, California

⁶Department of Genetics and Bioengineering, Yeditepe University, Istanbul Turkey, 34755

Abstract

Introduction—To detect a predictive protein profile that distinguishes between IL-2 therapy responders and non-responders among metastatic RCC patients we used surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI TOF-MS).

Materials and Methods—Protein extracts of 56 metastatic clear cell RCC patients obtained from radical nephrectomy specimens and prior to IL-2 therapy were applied to protein chip arrays of different chromatographic properties and analyzed using SELDI TOF-MS. A class prediction algorithm was applied to identify a subset of protein peaks whose expression values were associated with IL-2 response status. Multivariate analysis was performed to assess the association between the proteomic profile and the IL-2 response status controlling for the effect of lymphadenopathy.

Results—From a total of 513 protein peaks we discovered a predictor set of 11 peaks that performed optimally for predicting IL-2 response status (86 % accuracy, Fisher's $p < 0.004$,

© 2009 American Urological Association. Published by Elsevier Inc. All rights reserved.

Corresponding author: Jon Jones MD, BIDMC Genomics Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Harvard Institutes of Medicine, 4 Blackfan Circle, Boston, Massachusetts 02115, USA, Telephone: 617-667-0047, Fax:

617-975-5299, jjones6@bidmc.harvard.edu.

*H.H.O. and F.G. contributed equally

**AJP and TAL share senior authorship

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Competing interests statement: The authors declare that they have no competing financial interests.

permutation $p < 0.01$). The results were validated on an independent data set with an overall accuracy of 72% ($p < 0.05$, permutation $p < 0.01$). On multivariate analysis the proteomic profile was significantly associated with IL-2 response when corrected for lymph node status ($p < 0.04$).

Conclusions—We have identified and validated a proteomic pattern that is an independent predictor of IL-2 response. The ability to predict the probability of IL-2 response could permit targeted selection of patients most likely to respond to IL-2, while avoiding unwanted toxicities in patients less likely to respond. This proteomic predictor has the potential to significantly aid clinicians in the decision making of appropriate therapy for metastatic RCC patients.

Keywords

proteomics; metastatic Renal Cell Cancer; IL-2 therapy; surfaced-enhanced laser desorption/ionization time-of-flight mass spectrometry; biomarkers

Purpose

Renal Cell Cancer (RCC) has a heterogeneous clinical presentation with up to 30% metastatic cases at initial diagnosis and approximately 30% of initially organ-confined cases developing metastases during follow-up at variable intervals¹. Recently FDA approved oral agents for metastatic RCC offer improved progression free and overall survival, but essentially no complete responses². Aggressive treatment with radical nephrectomy and immunotherapy has also been shown to provide a survival benefit in metastatic RCC patients^{3, 4}, and retrospective data suggest that five-year survival rates were improved when IL-2 was used as adjunctive immunotherapy instead of IFN- γ (19.6% vs. 10%)⁵. Although the administration of IL-2 offers the possibility of durable CRs, it is associated with considerable toxicity, while only a small subset of patients respond to therapy³. Possible biomarkers for RCC such as carbonic anhydrase-IX (CA IX), Ki67 or PTEN have been published^{6, 7}. However, there is no reliable single marker available to identify those patients that are more likely to respond to IL-2 therapy, although factors such as regional lymphadenopathy, expression of CA-IX^{8, 9}, and selective pathologic subtypes have been proposed¹⁰.

Proteomics is an emerging field of science that attempts to study proteins in a massively parallel scale. Mass spectrometry (MS) based technologies such as MALDI (matrix assisted laser desorption/ionization), Surface enhanced laser/desorption ionization time of flight (SELDI-TOF MS), electrospray and ion trap have become the methods of choice in biomarker discovery and enable the separation of proteins and peptides according to their mass over charge (m/z) ratio. However, due to the large variations in concentrations of the proteome in tissues and bodily fluids most of the mass spectrometric approaches are not amenable to large numbers of patient samples. SELDI-TOF MS is one of few proteomic technologies suitable for high-throughput protein profile generation across a wide range of molecular weights, while proteins are retained on protein chips based on their binding affinity to the chip surface. While SELDI appears to be more sensitive in the low-mass range, which holds valuable information for biomarker discovery, SELDI by itself cannot identify protein IDs. Nevertheless, we have previously developed and validated a robotic approach to determine protein profiles with high reproducibility by SELDI-TOF MS^{11, 12}. In the current study our objective was to detect a protein profile that distinguishes between IL-2 treatment responders and nonresponders among metastatic RCC patients using SELDI TOF-MS.

Materials and Methods

Patients and tumor samples

56 prospectively archived frozen tissue samples from primary tumors of patients with metastatic clear cell RCC were obtained from the UCLA Kidney Cancer Program with approval from the institutional review board at UCLA and Beth Israel Deaconess Medical Center, Boston. All patients had undergone radical nephrectomy and adjunctive immunotherapy with recombinant IL-2 based therapy, and were evaluable for response. High dose IL-2 regimen consisted of up to two treatment cycles, each comprised of two treatment admissions separated by 10 days. For each admission, subjects were treated with 600,000 IU/kg via intravenous bolus infusion every 8 hours for up to 14 doses during a five day hospitalization. Response status was defined according to standard criteria defined at the time of the patients' evaluation and prior to the widespread adoption of RECIST (Response Evaluation Criteria in Solid Tumors).

Protein isolation

Approximately 50mg tissue was ground and lysed in 250µl lysis buffer consisting of 8M Urea, 2% CHAPS (3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate), 5mM DTT and 1% protease inhibitors. This mixture was vortexed and lysed with a micro-pestle for 10 minutes and centrifuged at $10,000 \times g$ at 4° C. The supernatant was then collected and the protein concentration was measured by Bradford assay. The protein concentration was normalized to 1µg/µl.

Mass Spectrometry

SELDI TOF-MS was performed using sample duplicates with the arrays described below. The entire procedure was carried out by a fully automated liquid-handling robot (Biomek FX™, Beckman Coulter).

Reversed Phase Chromatography

Hydrophobic protein arrays (H50 ProteinChip™ arrays; Ciphergen) were bulk washed with 50% acetonitrile (HPLC Grade; Aldrich) for 2×5 min, then loaded onto a 192-well bioprocessor (Ciphergen) and equilibrated with 10% acetonitrile/ 0.1% trifluoroacetic acid (Fisher Scientific). Each bioprocessor holds up to twelve 16-spot protein arrays and creates 100 µl wells above each spot. Ten µl of cell lysate were applied together with 50 µl binding buffer consisting of 10% acetonitrile/0.1% trifluoroacetic acid onto each array spot, and incubated for an hour. Array spots were washed 3×5 min with 75 µl 10% acetonitrile/ 0.1% trifluoroacetic acid, and 1×5 min with 75 µl water.

Cationic Exchange Chromatography

Weak cationic exchange chromatography protein arrays (CM10 ProteinChip™ arrays; Ciphergen) were pretreated with 10mM HCl for 5 min, and then rinsed with HPLC grade water. Subsequently, the arrays were loaded onto a 192-well bioprocessor, and equilibrated with 20mM ammonium acetate/0.1% Triton X-100 (Sigma), pH 6.0. Ten µl cell lysate and 50 µl 20mM ammonium acetate/ 0.1% Triton X-100 were dispensed onto each array spot, and incubated for one hour. The incubation comprised 60 cycles of pipetting the sample mixture up and down for 30 s. Array spots were washed 3×5 min with 75 µl 20mM ammonium acetate/ 0.1% Triton X-100 and 1×5 min with 75 µl water.

Immobilized metal affinity chromatography

Immobilized metal affinity capture arrays (IMAC30 ProteinChip™ arrays; Ciphergen) were incubated with 100mM CuSO₄ for 25 min and loaded onto a 192-well bioprocessor.

Subsequently, the arrays were equilibrated with 50 mM NaCl, 100mM NaH₂PO₄, pH 7.0. Ten µl cell lysate and 40 µl 50 mM NaCl, 100mM NaH₂PO₄, pH 7.0 were dispensed onto each array spot and incubated for an hour. Array spots were washed 3 × 5 min with 75 µl 500 mM NaCl, 100mM NaH₂PO₄, pH 7.0 to remove non-specifically bound proteins and then washed 5 minutes with 75 µl water.

Application of Matrix Molecule

SPA (sinapinic acid; Fluka), the matrix molecule, was prepared as a saturated solution in 50% acetonitrile/ 0.5% trifluoroacetic acid, and then diluted 1:1 in 50% acetonitrile/ 0.5% trifluoroacetic acid. After air drying arrays, 2 × 1 µl and 2 × 0.75 µl of SPA were dispensed to each spot of the hydrophobic, cationic exchange and IMAC arrays respectively, again using the Biomek FX™ (Beckman Coulter) equipped with a 96-channel 200 µl head. The arrays were air-dried again, and immediately analyzed.

Analysis

Peak detection—Protein peaks were defined by a signal-to-noise ratio ≥ 2.5 and detected using the Ciphergen Biomarker Wizard software. We interrogated the range of 2,000 – 40,000 Da for peaks and normalized the peak data with the total ion current method after baseline correction.

Data Set Split—The subjects were randomly divided into a training and validation set. The training set was used as a test-bed to find the predictive signature (peaks predictive for therapy response), which was then applied to the independent validation set, which had not been previously used to identify the predictive signature. The training set consisted of 16 non-responders (8 lymph node positive, 8 lymph node negative) and 12 responders (2 lymph node positive, 10 lymph node negative). The validation set consisted of 16 non-responders (9 lymph node positive, 7 lymph node negative) and 12 responders (2 lymph node positive, 10 lymph node negative).

Class Prediction—We identified a set of descriptive peaks (differentially expressed peaks between responders and non-responders) on the training data set using t-test ($p < 0.05$), assessed its significance using permutation testing (1000 permutations, 5% significance level) and chose peaks that remained significant after permutation analysis to account for multiple hypothesis testing¹³. The descriptive peaks were refined based on the accuracy of its subsets as predictor peaks on the training set using leave-one-out cross validation. We started this procedure on the training set with the responders and non-responders, and a set of features, the descriptive peaks. A sample was left out and a predictor set of peaks that distinguished the two groups was built and used to predict the class of the left-out sample. This procedure was cycled through all samples individually. The accuracy of the predictor equaled the total number of correctly predicted left-out samples. The best performing (highest leave-one-out accuracy) subset of the descriptive peaks was chosen as the predictive peak signature which was then applied to the validation set. Calculations of descriptive and predictive peaks were done solely on the training test. The finalized set of predictive peaks was then applied on the independent validation set, which was not used in obtaining the predictive signature. Class prediction was done using the k-nearest neighbor algorithm and the p-value for the predictor accuracy was calculated using Fisher's exact test¹³. The significance of the results was further assessed by a permutation test. The Mantel-Haenszel test was performed to assess the association between the proteomic profile and the IL-2 response status controlling for the effect of the lymph node status. Gene Cluster 2 (Whitehead Institute) and SPSS 11.0 were used as analysis software.

Clustering—A hierarchical clustering technique was used to construct an Unweighted Pair Group Method with Arithmetic-mean (UPGMA) tree using Pearson's correlation as the metric of similarity.

Results

The clinicopathological characteristics of the studied patients as well as the partitioning into training and validation set are presented in Table 1. There were no parameters with a statistically significant difference between training and validation set.

Out of the 56 metastatic patients 24 patients had responded and 32 patients had not responded to IL-2 therapy. Of the 24 responders, there were 22 partial and 2 complete responders according to RECIST.

Samples were spotted in duplicate and yielded highly reproducible spectra, as recently shown¹¹. The average intra-assay coefficient of variation was approximately 16%, which is within an acceptable range for SELDI studies¹¹. SELDI TOF-MS detected a total of 513 protein peaks on the ProteinChip™ arrays (165 on IMAC30, 206 on CM10 and 142 on H50).

We identified 23 descriptive peaks that differentiated responders from non-responders in the training set ($p < 0.05$, permutation $p < 0.05$). Figure 1 depicts the hierarchical clustering of the samples in the validation set using the 11 peak signature. These peaks were obtained by refinement of 23 descriptive peaks based on their leave-one-out prediction accuracy on the training set. This 11 peak signature displayed 86% leave-one-out cross validation accuracy (24/28 predicted correctly, $p < 0.004$; permutation $p < 0.001$) for the response status of the samples.

We then tested the 11-peak signature against samples in the validation set. The overall accuracy was 72% (20/28 predicted correctly, $p < 0.05$, permutation $p < 0.01$). Figure 2 presents a scattergram depicting the confidence values for prediction results for the training and validation sets¹³.

The trace view from the SELDI-TOF spectra of one of the 11 predictor peaks is shown representatively in Figure 3.

Because of the known association between lymph node status and response to IL-2 therapy, we examined the possibility that our results were confounded by lymph node status. Lymph node status was not associated with the SELDI predictions (Fisher's $p = 0.245$). Nonetheless, we performed multivariate analysis, which further showed that SELDI predictions were associated with IL-2 response independent of lymph node status ($p = 0.04$ by Mantel Haenszel test).

Discussion

The frustrating paucity of therapeutic options in metastatic RCC have led to the search for biomarkers that can aid in predicting prognosis and in selecting patients for appropriate therapy. Markers such as CAIX or Ki67 have been proposed for survival prediction in RCC⁶. In addition to individual markers, prognostic algorithms for survival in RCC patients have been developed through the use of select clinicopathological parameters such as 1997 classification T stage, Fuhrman's grade or lymph node status^{14, 15}. A more recent report focusing on metastatic RCC patients described an algorithm for survival prediction in patients after radical nephrectomy and IL-2 immunotherapy, which is to date considered the

therapy most likely to result in durable complete remissions for patients with metastatic RCC¹⁶.

IL-2 response, even when not complete, appears to be a surrogate for survival in metastatic RCC patients¹⁷. Considering the substantial toxicity of IL-2 therapy and the lack of reliable individual biomarkers for response, the objective of the current study was to discover a protein profile that could in the future enable the identification of the small subset of patients who are most likely to benefit from IL-2 therapy. This is to our knowledge the first report attempting the prediction of IL-2 response in metastatic RCC patients using proteomic analysis.

Using a highly standardized and automated procedure we used protein extracts from tumor sample tissue lysates of clear cell RCC patients with distant metastases who had undergone radical nephrectomy prior to receiving adjuvant IL-2 therapy, and applied them to three protein chip arrays of different chromatographic properties. Analysis of protein profiles revealed a pattern of 11 protein peaks predictive of IL-2 response that could be validated with 72% accuracy in an independent sample set (66% accuracy for responders, 75% for non-responders) ($p < 0.04$). Interestingly, lymph node status, which has been reported to be strongly associated with IL-2 immunotherapy response and is sometimes used in the clinical setting⁸, was accurate in only 62.5 % of the same sample set, highlighting the shortcoming of relying only on clinical variables to predict outcome. On multivariate analysis the result of the protein pattern remained statistically significant when controlled for lymph node status ($p < 0.01$). Clustering analysis shows that the 11-peak predictive signature can successfully distinguish between responders and non-responders (Figure 1).

Proteomic technologies, such as MS, provide the means to compare protein profiles identifying diagnostic or prognostic protein signatures. Protein profiling using SELDI-TOF MS has been successfully applied to derive protein signatures that distinguish several neoplastic entities¹⁸. Despite the limitations of SELDI-TOF MS with regard to resolution when compared to other MS technologies, the advantages of SELDI-TOF MS are the high throughput and sensitive acquisition of protein profiles from large numbers of patient samples in combination with on-chip protein fractionation that cannot be currently matched by other MS technologies¹⁹. While SELDI-TOF MS cannot directly identify the proteins in a protein profile, tandem MS is limited due to the requirement of extensive fractionation for protein identification, thus, dramatically decreasing sample throughput.

Thus, we have identified in our sample set a proteomic pattern that distinguishes and predicts IL-2 response and is an independent predictor of the lymph node status offering additional information. The clinical value of this molecular predictor will have to be validated prospectively in a larger independent data set. Our current study, however, provides the first “proof of principle” that such a proteomic profile can predict IL-2 therapy response in metastatic RCC patients.

High-dose IL-2 therapy produces tumor responses in 15–20% of metastatic RCC patients but individual prediction of treatment response is unreliable¹⁷. Prior ability to predict IL-2-response probability would allow the sparing of patients having a low probability of response from unwanted toxicities, making them candidates for alternative, investigational therapies. Future protein identification of some of the predictive peaks may, in addition, offer insights into the mechanisms underlying IL-2 responsiveness, and eventually lead to the development of alternative, more targeted treatment regimens.

Acknowledgments

Grant support: NIH grants K23CA095151-01 (AJP), 1RO1 CA85467, P50 CA090381, and RCC SPORE.

References

1. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. *J Urol.* 1998; 159:1163. [PubMed: 9507823]
2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *N Engl J Med.* 2007; 356:115. [PubMed: 17215529]
3. Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G. High-dose aldesleukin in renal cell carcinoma: long-term survival update. *Cancer J Sci Am.* 1997; 3(Suppl 1):S70. [PubMed: 9457398]
4. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. *N Engl J Med.* 2001; 345:1655. [PubMed: 11759643]
5. Pantuck AJ, Belldegrun AS, Figlin RA. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. *N Engl J Med.* 2001; 345:1711. [PubMed: 11759660]
6. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. *Clin Cancer Res.* 2003; 9:802. [PubMed: 12576453]
7. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, et al. Using protein expressions to predict survival in clear cell renal carcinoma. *Clin Cancer Res.* 2004; 10:5464. [PubMed: 15328185]
8. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. *Cancer.* 2003; 97:2995. [PubMed: 12784334]
9. Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. *Clin Cancer Res.* 2005; 11:3714. [PubMed: 15897568]
10. Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. *J Immunother.* 2005; 28:488. [PubMed: 16113605]
11. Aivado M, Spentzos D, Alterovitz G, Otu HH, Grall F, Giagounidis AA, et al. Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profiling. *Clin Chem Lab Med.* 2005; 43:133. [PubMed: 15843205]
12. Aivado M, Spentzos D, Gerding U, Alterovitz G, Meng XY, Grall F, et al. Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. *Proc Natl Acad Sci U S A.* 2007; 104:1307. [PubMed: 17220270]
13. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. *Science.* 1999; 286:531. [PubMed: 10521349]
14. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. *J Clin Oncol.* 2001; 19:1649. [PubMed: 11250993]
15. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. *J Urol.* 2002; 168:2395. [PubMed: 12441925]
16. Leibovich BC, Han KR, Bui MH, Panuck AJ, Dorey FJ, Figlin RA, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. *Cancer.* 2003; 98:2566. [PubMed: 14669275]
17. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. *Cancer J Sci Am.* 2000; 6(Suppl 1):S55. [PubMed: 10685660]
18. Kolch W, Mischak H, Pitt AR. The molecular make-up of a tumour: proteomics in cancer research. *Clin Sci (Lond).* 2005; 108:369. [PubMed: 15831087]

19. Poon TC. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. *Expert Rev Proteomics*. 2007; 4:51. [PubMed: 17288515]

Key of Definitions for Abbreviations

RCC	renal cell carcinoma
SELDI-TOF MS	surface-enhanced laser desorption/ionization time-of-flight mass




Figure 1.

Hierarchical clustering of the samples in the validation set using the 11-peak signature. R and NR stand for Responder and Non-Responder respectively. The lymph node status (lymph) is addressed by 0 and 1 as no cancer infiltration and present cancer infiltration, respectively. Rows represent the intensity values of individual peaks, which are normalized to $[-1, 1]$ as shown in the scale at the bottom. Peak labels represent the chip on which the peak was detected (I for IMAC30, C for CM10, H for H50) followed by the molecular weight for the detected peak. Red denotes an elevation while green denotes a decrease in expression.




Figure 2.

Scattergram depicting the confidence values for prediction results for both the training (2a) and validation sets (2b). X-axis is shown in bold red color denoting the separating line to make a decision for the response status. Samples that are above the line are predicted as non-responders and samples that are below the line are predicted as responders. True class labels

along with lymph node status are shown below each data point. Samples that are predicted in error are depicted using a colored background for the respective data labels.




Figure 3.

Trace view for one representative peak I 3606_65 (representing the peak on the IMAC30 chip with a molecular weight of 3,606.65 Da) from the 11-peak signature. The detection level for the peak (boxed) in 8 responders (R) and 8 non-responders (NR) is shown. Zooming of a spectrum shows the peak of interest as a picture in picture.

Table 1

Clinical and pathological characteristics of all patients.

Total no. of patients		56		
Gender *		Male 41 / Female 15		
Age *		Median 55 years (34–75)		
Histologic subtype *		Clear cell		
Response status		Responder (24 **) Non-Responder (32)		
Lymph node status		N+ (21) N0 (35)		
Data set split	Training		Validation	
n	28		28	
Response Status * Lymph Node Status *	12 Responders	2 LN +	12 Responders	2 LN+
		10 LN –		10 LN –
	16 Non-Responders	8 LN +	16 Non-Responders	7 LN+
		8 LN –		9 LN –

* Not significantly different in training and validation set (p>0.05)

** 22 partial and 2 complete responders according to RECIST